Io Therapeutics

Executive Summary

Io Therapeutics is a privately held biopharmaceutical company based in Spring, Texas, focused on discovering and developing small molecule therapeutics targeting nuclear receptors for the treatment of cancer, neurodegenerative, and autoimmune diseases. Founded in 2008, the company leverages its expertise in nuclear receptor biology to advance a pipeline of novel compounds. While specific program details are not publicly disclosed, Io Therapeutics continues to pursue preclinical and early-stage clinical development. The company's approach aims to modulate nuclear receptors involved in disease pathways, potentially offering differentiated mechanisms of action. Given its private status and limited public information, the company's progress is not widely tracked, but it remains active in the competitive biotech landscape.

Upcoming Catalysts (preview)

• TBDIND Filing for Lead Nuclear Receptor Agonist40% success
• H2 2026Presentation of Preclinical Data for Neurodegenerative Program70% success
• TBDStrategic Partnership or Licensing Deal30% success